PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Insulin-like Growth Factor 1 Long R3
💉Growth FactorIGF-1 analog with extended half-life for muscle cell hyperplasia (new cell creation, not just hypertrophy). Promotes nitrogen retention and protein synthesis.
IGF-1 LR3 demonstrates significantly enhanced potency over native IGF-1 due to reduced binding protein affinity and extended half-life, promoting dose-dependent muscle growth.
preclinicalPhilippou & Barton (Growth Hormone & IGF Res.): Comprehensive review of IGF-1's role in muscle satellite cell activation, myoblast proliferation, and skeletal muscle regeneration.
preclinicalBowers et al.: Meta-analysis of epidemiological studies examining positive correlation between circulating IGF-1 levels and prostate, breast, and colorectal cancer risk.
moderate strongPotent; use caution. Risk of hypoglycemia. Theoretical cancer promotion concern well-documented in literature. Research-only.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Very low doses. Inject post-workout for localized muscle effects. Monitor blood sugar closely. Short cycles only.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
Enhanced nutrient partitioning; increased post-workout pumps
Weeks 2-4
Lean mass and recovery improvements; possible hypoglycemia if undereating
Month 2-3
Significant body composition changes; hyperplasia (new cell creation) possible
Long-term
Theoretical cancer promotion risk with chronic use; short cycles essential
| Side Effect | Incidence | Severity |
|---|---|---|
Hypoglycemia Especially if dosed without food nearby; have glucose on hand | ~10% of users | moderate |
Joint pain | ~8% of users | mild |
Headache | ~5% of users | mild |
Fluid retention | ~10% of users | mild |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Maximize lean muscle gain through GH optimization, growth factor signaling, and myostatin inhibition
Weekly Peptide Research
New studies · vendor alerts · protocol tips
No spam. Unsubscribe anytime. Research use only.